April 28th, 2021
AAIDA hosted speciality pharmacist, Michael Rigas, PharmD, for our 5th educational webinar and first “forum” event of 2021.
Dr. Rigas will discuss the following during his presentation:
- What is IVIG and how is it made
- What diseases can IVIG be used to treat and what responses and side effects are expected
- What IVIG products are currently available and what are their characteristics
Dr. Rigas is the Chief Clinical Officer, co-founder and principal at KabaFusion, an infusion therapy company dedicated to managing IVIG and other chronic and acute therapies nationwide. Prior to joining KabaFusion, Dr. Rigas was Associate Chief Innovation Officer for Pharmaceutical Care for Geisinger Health System and Chief Clinical Officer for VITALine CareSite Pharmacy Services.
Dr. Rigas graduated from USC School of Pharmacy with his Pharm.D. degree and completed his residency at UC San Francisco Hospitals and Clinics in 1982. His areas of expertise include antimicrobial therapy, immunoglobulin therapies (IVIG), nutritional support, inotropic therapies and many others.
Dr. Rigas has worked on standardized coding for infusion billing, universal access via patient assistance plans and managing Medicare Part D issues in front of the California board of pharmacy and CMS regional managers. Dr. Rigas is a member of the American Society of Hospital Pharmacists, the National Home Infusion association, the American Academy of Neurology and the Clinical Immunology Society. Over the last 20 years, Dr. Rigas has managed or overseen the care of over 15,000 patients who have received over 20,000,000 grams of IVIG.